日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway.

TRPV4 通过促进 ECM1 生成和共同激活 FAK/PI3K/AKT/GSK3β 通路来驱动平滑肌肉瘤的进展

期刊:Cellular Oncology
影响因子:4.8
doi:10.1007/s13402-024-01008-7
Zhou Qiwen, You Yang, Zhao Yingying, Xiao Shuxiu, Song Zhengqing, Huang Chuxin, Qian Jiali, Lu Weiqi, Tong Hanxing, Zhang Yong, Wang Zhiming, Li Wei, Zhang Chenlu, Guo Xi, Luo Rongkui, Hou Yingyong, Cui Jiefeng, Lu Lili, Zhou Yuhong
信号转导
PI3K/Akt
发表日期：2025
文献求助 收藏

LAYN Serves as a Prognostic Biomarker and Downregulates Tumor-Infiltrating CD8(+) T Cell Function in Hepatocellular Carcinoma

LAYN 可作为预后生物标志物，并下调肝细胞癌中肿瘤浸润 CD8(+) T 细胞的功能

期刊:Journal of Hepatocellular Carcinoma
影响因子:3.4
doi:10.2147/JHC.S464806
Xiao, Shuxiu; Lu, Lili; Lin, Zhiyuan; Ye, Xinming; Su, Sheng; Zhang, Chenlu; You, Yang; Li, Wei; Huang, Xiaowu; Wu, Weizhong; Zhou, Yuhong
肿瘤
T细胞
肿瘤免疫
CD8
细胞生物学
发表日期：2024
文献求助 收藏

Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib

肿瘤浸润性B淋巴细胞（TIBs）与接受抗PD-1抗体联合阿昔替尼治疗的转移性透明细胞肾细胞癌（mccRCC）患者的不良临床结局、不利的治疗获益和免疫抑制环境相关。

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-024-05803-5
Lin, Zhiyuan; Xiao, Shuxiu; Qi, Yu; Guo, Jianming; Lu, Lili
肿瘤
肿瘤免疫
肾癌
细胞生物学
PD-1
免疫/内分泌
发表日期：2024
文献求助 收藏